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AbstrAct
Based on a series of basic, preclinical and clinical studies, the Poly (ADP-
ribose) Polymerase 1 (PARP1) inhibitor, olaparib, has recently been approved for 
use in ovarian cancer patients with BRCA1 or BRCA2 mutations. By identifying novel 
predictive biomarkers of tumour cell sensitivity to olaparib, it is possible that the 
utility of PARP inhibitors could be extended beyond this patient subgroup. Many 
of the known genetic determinants of PARP inhibitor response have key roles in 
DNA damage response (DDR) pathways. Although protein ubiquitylation is known to 
play an important role in regulating the DDR, the exact mechanisms by which this 
occurs are not fully understood. Using two parallel RNA interference-based screening 
approaches, we identified the E3 ubiquitin ligase, CBLC, as a candidate  biomarker of 
response to olaparib. We validated this observation by demonstrating that silencing 
of CBLC causes increased sensitivity to olaparib in breast cancer cell line models and 
that defective homologous recombination (HR) DNA repair is the likely cause. This 
data provides an example of how defects in the ubiquitin machinery have the potential 
to influence the response of tumour cells to PARP inhibitors.
IntroductIon 
The poly (ADP-ribose) polymerase, PARP1 plays a 
key role in the repair of damaged DNA [1]. Upon binding 
damaged DNA, PARP1 uses β-NAD+ as a co-factor to 
synthesise poly (ADP-ribose) chains on a series of target 
proteins [1]. This PARylation of PARP1 substrates initiates 
the localisation of a series of DNA repair mediators to the 
site of DNA damage, before autoPARylation of PARP1 
causes its release from DNA [1]. Over the past few years, 
a number of small molecule inhibitors of PARP1 have 
been developed for the treatment of cancer [2]. Pre-clinical 
work demonstrated that these inhibitors cause synthetic 
lethality in tumour cells with BRCA1 or BRCA2 gene 
defects [3, 4], an observation that has also been confirmed 
in clinical trials [2, 5]. It seems likely that the sensitivity of 
BRCA defective tumour cells to PARP inhibitors is caused 
by their characteristic defect in repair of DNA double 
strand breaks (DSBs) by homologous recombination (HR), 
a process controlled by BRCA1, BRCA2 and the DNA 
recombinase RAD51 [3]. Although various mechanisms 
to explain this synthetic lethality have been proposed, one 
hypothesis is that PARP inhibitors restrict the release of 
PARP1 from damaged DNA [6]. The DNA lesion that 
results from the trapping of PARP1 on DNA likely stalls 
DNA replication forks and requires functional HR for its 
repair [6, 7].
In addition to defects in BRCA1 and BRCA2, 
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preclinical work has suggested that alterations in a series 
of additional genes also modulate the response to PARP 
inhibitors. In totality these efforts have identified a number 
of candidate predictive biomarkers of tumour cell response 
including ATM, ATR, CHEK1, CHEK2, DSS1, RAD51, 
NBS1, IPMK, NAMPT, ERCC1, the Fanconi anaemia 
complementation genes, PTEN and the TMPRSS2–
ERG and EWSR1-FLI1 translocations (reviewed in 
[2]). Recently, we also described a genome-wide RNA 
interference screen that identified a compendium of novel 
PARP inhibitor sensitivity-causing genes, including the 
kinase-coding gene CDK12 [8].
The majority of PARP inhibitor sensitivity genes 
identified to date have a known role in DNA double 
strand break repair (DSBR). In part, the DSB signalling 
and repair process is controlled by ubiquitylation, the 
post-translational, covalent attachment of 76 amino-
acid ubiquitin chains to target proteins (reviewed in 
[9,10]). Ubiquitylation is mediated via the coordinated 
activity of E1 (ubiquitin activating), E2 (ubiquitin-
conjugating) and E3 (ubiquitin ligase) enzymes and can 
be reversed by the activity of de-ubiquitylating enzymes 
(DUBs) (reviewed in [9]). The role of these enzymes in 
DSB detection and repair is best exemplified by their 
involvement in the recruitment of key DSBR proteins 
to the site of DNA damage. For example, DNA double 
strand breaks are recognised by the MRN (Mre11–Rad50–
NBS1) complex, an event that leads to the activation of 
signalling kinases that phosphorylate the histone H2AX 
on chromatin that flanks the site of DNA damage. This in 
turn enables the recruitment and phosphorylation of the 
DSBR mediator, MDC1. Once located to a DSB, MDC1 is 
itself phosphorylated; the phosphorylated amino acids on 
MDC1 are bound by the E3 ligase RNF8, which initiates 
a series of ubiquitylation events that ultimately recruit 
the E3 ligase RNF168. Together the RNF8 and RNF168 
ubiquitylation events enable the recruitment and retention 
of a series of DSBR factors including BRCA1, which 
also has E3 ligase activity and drives DSBR by HR, and 
53BP1, whose activity drives DSBR via an alternative 
process known as Non Homologous End Joining 
(reviewed in [9, 10]). In addition to the role of E1, E2 
and E3 enzymes in these processes, a recent systematic 
analysis of DUBs, which remove ubiquitin residues from 
proteins, has highlighted the role of these enzymes in 
DSBR and the maintenance of genomic integrity [11]. 
Given the known role of ubiquitin metabolism 
in DSBR and the response to PARP inhibitors being 
determined by this process, we assessed the possibility 
that additional genes involved in ubiquitin metabolism 
might alter the tumour cell response to PARP inhibitors. 
To do this, we have performed a high-content microscopy-
based genetic screen for ubiquitylation-related genes, 
along with parallel analyses of data from a recent genome-
wide RNA interference screen and integrated these 
two complementary datasets in this study. Below, we 
describe these parallel approaches, as well as functional 
studies that together pinpoint the ubiquitin ligase CBLC 
as a previously unrecognized factor whose depletion is 
synthetically lethal with PARP inhibition.
results 
Genome-wide PARPi shRNA screen identifies 
candidate olaparib sensitisation genes involved in 
the control of ubiquitylation
To investigate the possibility that proteins involved 
in the ubiquitylation machinery modulated the tumour 
cell response to a clinical PARP inhibitor, olaparib [3, 
12], we first reanalyzed data from a previously published 
genome-wide olaparib sensitization genetic screen [8]. 
In this screen, an olaparib resistant, BRCA1, BRCA2 
and p53 wild-type breast tumour cell line, MCF7, was 
transduced with a lentiviral library encompassing 57,540 
short hairpin (sh)RNA expression constructs designed 
to target 16,487 unique human protein-coding genes. 
The virally transduced cell population was subsequently 
divided into two cohorts, one exposed to olaparib for 
two weeks, the other exposed to the drug vehicle. By 
comparing shRNA frequencies in olaparib vs. vehicle 
surviving cell populations after two weeks, we identified 
2,208 different genes whose gene silencing was predicted 
to result in enhanced olaparib sensitivity (those shRNAs 
that gave an olaparib sensitization Z score <-2) [8]. By 
re-annotating the candidate olaparib sensitisation genes 
identified in this screen using pathway annotation tools 
such as KEGG, we identified a series of genes implicated 
in the control of ubiquitylation that were also implicated 
in olaparib sensitivity (Table 1). This gene list included 
both E1 Ubl-activating enzymes, E2 Ubl-conjugating 
enzymes as well as E3 Ubl-protein ligases and included 
known determinants of PARP inhibitor sensitivity such as 
BRCA1 [3] as well as the UBA1 E1 enzyme coding gene, 
previously reported to be required for responses to IR and 
replication stress in human cells (Supplementary Figure 1) 
[13]. Amongst these olaparib candidate sensitivity genes, 
we also noted RNF168, which is known to play a key role 
in the recruitment of a series of DSBR factors [9, 10, 14] 
as well as a series of DUB enzyme-coding genes. These 
latter genes included BAP1, required for histone H2A 
deubiquitylation [15], BRCC36 (BRCC3) which has been 
associated with the in vitro response to the clinical PARP 
inhibitor rucaparib [16] and USP7S, whose gene product is 
involved in controlling the p53 response to DNA damage 
[17].
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Table 1: Genes implicated in Ubl metabolism identified as candidate olaparib sensitivity genes in 
[8]. The extent of olaparib sensitisation is indicated by the median Z score. Negative Z scores indicate a 
sensitization effect.
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table 2: Genes implicated in olaparib sensitivity as scored by automated micronuleation analysis. Hits 
are defined as those that showed more than 31 MN in the presence of Olaparib and 15 or less MN in DMSO.
MIcronucleAtIon HIts
4 of 4 (3) 3 of 4 (14) 2 of 4 (104)
CUL7 ANAPC1 ANAPC2 HGS RNF149
MAP3K7IP2 ASB6 ANAPC7 HIC1 RNF182
MYO1E ATR ANKRD13A HLTF RNF187
DHX9 ASB11 JARID1A RNF19A
ERLIN1 ASB14 KALRN RWDD2A
MDM1 ASB15 KBTBD6 SENP2
POLK ASB17 KBTBD7 SENP5
RNF17 BAG1 KIAA0999 SENP8
RNF4 BCL6B KIAA1333 SHPRH
STAMBPL1 BIRC2 LNX2 SMURF2
UBE2H BMI1 LRPPRC SQSTM1
UBQLN1 BTBD14A MARCH10 STUB1
ZBTB3 CAND2 MARK2 SUGT1
ZNF395 CBLL1 MKRN2 TBK1
CCNF MLL2 TEX13A
CDH1 NOSIP TMEM183A
COPS3 NSD1 TOM1
COPS5 NSFL1C TOPBP1
CSMD3 NSMCE2 TRAF3
DDB2 OTUD5 TRAF5
DERL2 OTUD7A TREX2
DIP2C PARD6B TRIM23
DSG1 PHF12 TRIM8
DTX4 PHF21A TTC3
EIF2AK4 PHF7 UBL3
EPN3 POLI UBL4B
FAM100A PSMA5 UBXD5
FAU PSMA8 USP45
FBXO34 PSMF1 VSP13A
FBXW11 PYGO2 WDR24
FZR1 RB1CC1 WDR32
G3BP1 RCBTB1 XAF1
GZF1 RFPL2 ZBTB17
HADHA RFWD2 ZNFX1
HECTD1 RNF139
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A parallel high-content microscopy-based 
genetic screen identifies ubiquitylation-related 
determinants of PArP inhibitor sensitivity
In parallel to the genome-wide genetic screen, we 
also carried out a focused high-content genetic screen 
to identify genes associated with ubiquitin metabolism 
that are synthetically lethal with PARP inhibition. In this 
screen, the human U2OS osteosarcoma-derived cell line 
was plated on an siRNA array designed to target 1346 
human genes involved in the ubiquitin-metabolism, 
the proteasome system and genes encoding zinc-finger 
proteins [13]. Following siRNA transfection, cells were 
exposed to either olaparib or the drug vehicle, DMSO for 
three consecutive days (Figure 1A). At this point, cells 
were fixed, nuclei stained with Hoechst and images of 
cell nuclei were automatically acquired using wide-field 
fluorescence microscope. We estimated the effect of each 
siRNA on olaparib sensitivity and genomic instability 
using two approaches. First, we counted micronuclei 
formation as an estimate of genomic instability caused 
by PARP inhibitor exposure using an automated ImageJ-
based programme, and compared micronuclei frequency in 
olaparib and vehicle exposed cells (Table 2). In parallel, 
we also used manual scoring of nuclear and mitotic 
defects (multinucleation, irregularity of nuclear shape and 
anaphase chromosome bridges) (Table 3). 
In both sets of analyses, we used our previously 
established high-content microscopy-based screening 
strategy [13,14] and assessed the phenotypes in four 
independent transfections, imaging approximately 150 
cells that usually occupy each individual siRNA spot. 
Across the entire screen, our automated analysis examined 
the average number of micronuclei for each of the 
computer-identified multicellular siRNA spots. In control 
DMSO-exposed cells this overall micronuclei score was 
2.63, while in control olaparib-exposed cells, this overall 
average score was 15.35 (baseline average score). We 
considered as “hits” those siRNAs that elicited a greater 
than two-fold increase (30.7 or more micronuclei/spot) in 
the frequency of micronuclei when exposed to olaparib, 
but did not cause an alteration in micronuclei frequency 
in DMSO exposed cells. Using this approach, the 
automated imaging analysis identified three genes (CUL7, 
MAP3K7IP2, MYO1E) that enhanced olaparib-induced 
micronucleation in all four transfections, 14 genes with 
three out of four transfections scoring positively, and 
104 genes where two out of four transfections elicited 
micronucleation in response to PARP inhibitor exposure 
(Table 2). An example of the PARP inhibitor induced 
micronucleation phenotype is shown in Figure 1B, where 
the effect of the siRNA targeting ANAPC1 (anaphase 
promoting complex subunit 1), an E3 ubiquitin ligase 
coding gene is shown. We noted that ANAPC1 also scored 
in the genome-wide shRNA olaparib sensitivity screen as 
a determinant of olaparib sensitvity (DE Z score of -2.15, 
Table 1).
Using manual scoring, no single gene scored in 
all four transfections but we identified two genes where 
siRNA caused aberrations in the examined nuclear 
parameters in the olaparib exposed cells in three out of 
four transfections; the known olaparib sensitivity gene 
ATR (ATR serine/threonine kinase) and FBXO5 (F-box 
protein 5, Table 3) a new olaparib-sensitizing factor 
identified in our present screen. siRNA targeting 21 genes 
caused nuclear defects in the olaparib exposed cells in 
two out of four transfections (Table 3). Of these genes, 
we noted that the siRNA designed to target the E3 ligase 
coding gene CBLC (Cbl proto-oncogene C [18]) caused 
pronounced nuclear aberrations in olaparib-exposed cells 
but not in control DMSO-exposed cells (Figure 1B). 
shRNA designed to target CBLC also caused one of the 
most profound olaparib sensitisation effects in the MCF7 
genome-wide shRNA interference screen (Z score -7.67, 
Table 1). By comparison, shRNA targeting BRCA1 gave 
an olaparib drug sensitisation Z score of -4.38.
cblc silencing causes a Hr defect
Given the profound effect of shRNA targeting CBLC 
in the genome-wide genetic screen in MCF7 cells and 
the effect of siRNA targeting CBLC on olaparib-induced 
nuclear defects in U20S cells, we assessed the extent of 
PARP inhibitor sensitivity caused by CBLC silencing in 
dose-response clonogenic survival experiments. When 
compared to a control, non-targeting shRNA expression 
construct, two different CBLC shRNA expression 
constructs caused a profound and significant increase in 
olaparib sensitivity in MCF7 cells (Figure 2A, olaparib 
survival in shCONTROL targeted cells vs. shCBLC 
targeted cells, p<0.0001 ANOVA, and Figure 2B). We 
found the extent of olaparib sensitivity caused by CBLC 
shRNA to be equivalent to that caused by an shRNA 
expression construct designed to target BRCA1 (Figure 
2A). We also found that siRNA reagents designed to target 
CBLC caused olaparib sensitisation in MCF7 cells as well 
as in a second breast tumour cell line model, HS578T 
(Figure 2C,D,E), suggesting that these effects were neither 
restricted to the method of RNA interference used nor to 
the MCF7 cell line model used in the original genome 
wide shRNA screen.
One key molecular determinant of tumour cell 
response to PARP inhibition is the ability to localise the 
DNA recombinase RAD51 to the site of DNA damage, 
a critical event in HR repair that can be monitored by 
the immunodetection of DNA damage induced RAD51 
foci [3, 19]. We assessed the RAD51 response in human 
tumour cells transfected with CBLC siRNA, as well 
as the formation of γH2AX foci, a marker of histone 
H2AX phosphorylation that is associated with DNA DSB 
formation [20]. Whilst control-transfected MCF7 cells 
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Figure 1: Focused siRNA screen for Ubl modifiers of the PARP inhibitor response. A. Screening procedure. U2OS cells 
were plated on siRNA arrays and 24 h later treated with 10 uM Olaparib or vehicle (DMSO). After 3 days of cultivation cells were fixed, 
cells nuclei were stained with Hoechst and images corresponding to each siRNAs acquired using automated routine. Scoring was done in 
two ways; first using automated routine in program ImageJ number of micronuclei was determined. Manual scoring of nuclear and mitotic 
defects was employed as another way to determine which siRNA knockdowns sensitize cells to Olaparib. B. Images of Hoechst stained cell 
nuclei from siRNA screen illustrating the effect of siRNA targeting CBLC. 
table 3: Genes implicated in olaparib sensitivity by manual scoring of nuclear and mitotic defects. 
MANUAL SCORING HITS
4 of 4 (0) 3 of 4 (2) 2 of 4 (21)
ATR ANUBL1
FBOX5 ARIH1
AURKA
CBLC
CCNF
CDC20
CDC27
CUL1
DDB1
DDB2
DHX9
DPF2
FBXW7
PEX10
PHF21A
PIAS4
RNF17
RNF4
SKP1
SPSB2
UBQLN3
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Figure 2: cblc gene silencing causes PArP inhibitor sensitivity. A. Clonogenic dose-response survival curves from MCF7 
human breast cancer cells infected with shRNA expression constructs targeting either BRCA1 or CBLC. Transduced cells were subsequently 
exposed to olaparib for 14 days at which point cell colonies were counted. Two different shRNA expression constructs targeting CBLC, 
shCBLC_1 and shCBLC_2, were used.****ANOVA p value <0.0001 for the dose response curves in either shCBLC_1 or shCBLC_2 
transduced cells vs. shCONTROL transduced cells. Data from shBRCA1 transduced cells is shown as the positive control. B. Bar chart 
illustrating CBLC RT-PCR data from MCF7 cells expressing CBLC cDNA and transduced with shRNA expression constructs. *Student’s 
t test p value <0.05 for CBLC expression compared to shCONTROL tranduced cells. C. and D. Olaparib dose-response survival curves 
from MCF7 (C) or HS578T (D) human breast cancer cells transfected with siRNA targeting either BRCA2 or CBLC. Cells were transfected 
with siRNA and 48 hours later exposed to olaparib for a subsequent six days.****ANOVA p value <0.0001 for the dose response curves 
in siCBLC transfected cells vs. siCONTROL transfected cells. Data from siBRCA2 transfected cells is shown as the positive control. E. 
Bar chart illustrating CBLC RT-PCR data from MCF7 cells expressing CBLC cDNA and transfected with siRNA. * Student’s t test p value 
<0.05 for CBLC expression compared to siCONTROL transfected cells. Where error bars are shown these represent the standard error of 
the mean (SEM) from three independent experiments.
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exhibited a clear increase in both RAD51 and γH2AX 
foci in response to ionising radiation (IR) (Figure 3A and 
B), cells transfected with either CBLC or BRCA2 siRNA 
exhibited a clear reduction in the frequency of cells 
exhibiting a RAD51 foci response (Figure 3A and B). In 
addition to the RAD51 defect, we also noted that 24 hours 
after the initial exposure to IR, the frequency of cells still 
exhibiting γH2AX foci, and presumably unrepaired DSBs, 
was moderately increased in cells transfected with siRNA 
targeting either CBLC or BRCA2 (Figure 3B), compared 
to those transfected with a control siRNA. 
Taken together, these results suggested that a CBLC 
defect could cause a reduction in the ability to repair DNA 
by homologous recombination (HR). To directly assess 
the effect of CBLC silencing on HR, we estimated HR 
activity using a synthetic DNA HR substrate, DR-GFP, 
Figure 3: cblc gene silencing causes a homologous recombination defect. A and B. Bar charts indicating the frequency of 
cells with greater than five RAD51 (A) and γH2AX (B) nuclear foci in response to exposure to 10 Gy ionising radiation and CBLC siRNA. 
CBLC siRNA reduced the frequency of cells with RAD51 foci * p<0.05 Student’s t test vs. control siRNA transfected cells at the same time 
point. Data from siBRCA2 transfected cells is shown as a positive control. C. Bar chart indicating GFP signal generated by repair of the 
DR-GFP DNA substrate. Data shown is normalised to the % of GFP positive cells in a mock-transfected sample. CBLC siRNA reduced the 
frequency of GFP+ve cells *p<0.05 Student’s t test vs. control siRNA transfected cells. Data from siBRCA2 transfected cells is shown as 
a positive control. Where error bars are shown these represent the standard error of the mean (SEM) from three independent experiments.
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which generates a GFP signal once an experimentally 
induced DSB has been repaired by HR [21]. We found that 
the repair of the DR-GFP substrate by HR was impaired 
in both BRCA2 and CBLC siRNA transfected cells 
compared to control transfected cells (Figure 3C, p<0.05 
by student’s t-test), supporting the hypothesis that loss 
of CBLC activity causes a HR defect, a phenotype that 
could explain the PARP inhibitor sensitivity also caused 
by loss of CBLC function. We also assessed the effect 
on progression of the MCF7 breast cancer cells through 
the cell cycle in response to CBLC silencing. In both 
the presence and absence of IR exposure, we found that 
CBLC siRNA caused a modest reduction in the relative 
frequency of cells in both S and G2 phases of the cell 
cycle (Supplementary Figure 2A and B). These alterations 
were similar to those elicited by siRNA targeting BRCA2 
(Supplementary Figure 2A and B). 
Based on these analyses, we conclude that depletion 
of CLBC sensitizes diverse human cancer cells to the 
PARP inhibitor olaparib and causes defects in cellular 
responses to DNA double strand breaks including Rad51 
foci formation and HR repair. Furthermore, the extent 
of the observed phenotypes after CBLC depletion was 
comparable to depletion of BRCA2, one of the key HR 
factors currently being used to direct the clinical use of 
PARP inhibitors. 
dIscussIon 
In the work described here, we used a reanalysis 
of a genome-wide genetic screen [8] together with a 
focused siRNA screen and identified and validated a 
novel genetic determinant of tumour cell PARP inhibitor 
sensitivity, the ubiquitin ligase CBLC [18]. siRNA 
targeting CBLC enhanced the extent of nuclear defects 
monitored as a readout in the focused screen in cells 
exposed to the clinical PARP inhibitor olaparib and 
impaired DNA damage-induced RAD51 foci formation. 
This suggested that the cause of PARP inhibitor sensitivity 
in cells depleted of CBLC might be defective homologous 
recombination. This hypothesis was also supported by 
our experiments using a synthetic HR DNA substrate, 
the results of which were consistent with the concept of 
homologous recombination being indeed defective when 
CBLC is silenced. 
CBLC encodes an E3 ubiquitin ligase of the CBL 
family, whose other members include CBL (also known 
as c-CBL) and CBLB [18]. Like CBL and CBLB, CBLC 
has a highly conserved N-terminus that encompasses a 
phosphotyrosine binding domain and a catalytic ring finger 
domain [22, 23]. Compared to CBL and CBLB, relatively 
little is known about the function of CBLC. Similar to 
CBL and CBLB, CBLC binds SH3 (SRC Homology 3) 
domain containing proto-oncogenic tyrosine kinases such 
as EGFR (Epidermal Growth Factor Receptor), LYN, 
CRK, SRC and RET [22, 24, 25]. EGF-triggered activation 
of EGFR results in CBLC being recruited to the receptor 
where CBLC is phosphorylated. The interaction between 
CBLC and EGFR leads to the attenuation of MAP kinase 
signalling [22]. Likewise, CBLC enhances ubiquitylation 
and degradation of the oncoprotein RET [26, 27]. CBLC 
has also been shown to form a complex with HIC5 
(Hydrogen peroxide-inducible clone 5) and the heat shock 
protein HSP27. These latter interactions are thought to 
be required for the ubiquitylation of NOX4, a protein 
involved in the control of reactive oxygen species [28] 
and diverse stress-induced cellular responses including 
oncogene-induced cell senescence [29]. It remains to 
be seen whether any of the known interactions with 
CBLC are responsible for the PARP inhibitor sensitivity 
phenotype we have observed here or whether another, as 
yet unidentified, CBLC substrate mediates these effects. 
As far as we are aware, this is the first report to 
link CBLC to a DNA repair related function. Compared 
to other genes implicated in HR and PARP inhibitor 
sensitivity, CBLC mutations are relatively rare in cancer, 
being present in approximately 2 % of 4000 human 
tumours whose exome sequence is described on the cBio 
database [30, 31] This of course does not exclude the 
possibility that impaired CBLC transcription, translation 
or reduction in CBLC protein levels by enhanced turnover 
could cause sensitivity to a PARP inhibitor. Unlike its 
relatives within the CBL family, CBLC expression appears 
to be restricted to epithelial tissues [32,33]. Transgenic 
expression of CBLC in a mouse mammary gland causes 
impairment of cell proliferation, suggesting that CBLC 
might have a growth-inhibitory role [32]. The role that 
CBLC plays in DNA repair by homologous recombination, 
described here, might suggest that this ubiquitin ligase 
could represent a candidate for a novel tumour suppressor. 
It is therefore plausible that transcriptional, translational 
or proteolytic suppression of CBLC in tumours might be 
a more common event than gene mutations. Furthermore, 
in contrast to defects in genes such as BRCA1 [34], 
constitutive Cblc deficiency is neither embryonically 
lethal in mice nor overtly harmful in somatic cells of adult 
Cblc deficient animals [33]. 
Given the recent regulatory approval in the USA and 
Europe for olaparib (now named Lynparza) as a treatment 
for BRCA1/2-deficient ovarian tumours [5], the functional 
assessment and validation of candidate biomarkers is most 
timely. Apart from the emerging sensitivity biomarkers 
identified through synthetic lethal interactions with 
PARP inhibitors [1,2,7,8,12,34-38], several molecular 
determinants of enhanced resistance in BRCA-deficient 
tumours, such as revertant BRCA gene mutations, loss 
of p53BP1 or JMJD1C have been reported and their 
predictive value requires careful evaluation [2,34,39-41]. 
Similarly, it remains to be seen whether CBLC modulates 
the clinical response to PARP inhibitors, but the work 
described here suggests that along with other genes that 
are known to control homologous recombination, CBLC 
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should be considered as a candidate biomarker of response 
and potentially assessed in biopsy material from patients 
enrolled on existing and future PARP inhibitor clinical 
trials [2].
MAterIAls And MetHods
cell lines
Human U2OS cell line was cultured in Dulbecco’s 
Modified Eagle’s medium (DMEM) supplemented with 
10% (v/v) foetal bovine serum (Invitrogen, Carlsbad, 
CA, USA) and penicillin/streptomycin (Sigma-Aldrich, 
St. Louis, MO, USA). Human MCF7 and Hs578T cell 
lines were grown in RPMI 1640 or DMEM supplemented 
with 2mM glutamine, 10% (v/v) foetal bovine serum and 
penicillin/streptomycin respectively. 
chemicals
PARP inhibitor olaparib was purchased from 
Selleckchem and was dissolved in DMSO (Sigma-Aldrich, 
St. Louis, MO, USA).
shrnA screen analysis
Median drug effect Z score data from [8] was used. 
Genes with median drug effect Z scores of <-2 in [8] were 
cross referenced with gene listed in the following KEGG 
groups to generate the data shown in Table 1: Ubiquitins 
and Ubiquitin-like proteins, Ubiquitin-activating enzymes 
(E1), Ubiquitin-conjugating enzymes (E2), Ubiquitin 
ligases (E3), Deubiquitinating enzyme (DUB). 
targeted ubiquitin-proteasome sirnA-based 
screen
A custom-designed siRNA arrays were described 
previously [13]. U2OS cells were plated on siRNA arrays 
and 24 h later exposed to 10 µM Olaparib or DMSO. 
Olaparib treated arrays were prepared in duplicate. 
After 72 h of cultivation cells were fixed and stained 
with Hoechst (Invitrogen, Carlsbad, CA, USA). Image 
acquisition of the siRNA arrays was described previously 
[13]. The number of micronuclei was determined by 
automated routine using software ImageJ (http://rsb.
info.nih.gov/ij/). In addition to automatic scoring of 
micronuclei induction, manual scoring based on other 
nuclear and mitotic defects (multinucleation, irregularity 
of nuclear shape, anaphase bridges) was employed. Hits 
were defined based on number of micronuclei (MN) in 
Olaparib control siRNA (siCON + Olaparib) treated cells, 
where average number of MN per siRNA spot in whole 
screen was 15.35. Threshold for hits in Olaparib treated 
cells was set as twice that number (2 x 15.35 = 30.7). As 
hits were considered siRNAs with more than 31 MN in the 
presence of Olaparib and 15 or less MN in DMSO control.
Hr assay
A synthetic repair reporter was used as previously 
described [8]. HeLa cells harboring a single-copy genomic 
integration of the DR-GFP reporter were transfected with 
siRNA targeting CBLC, BRCA2 or a siControl. 24 hours 
later, cells were transfected with the I-SceI expression 
vector, pcBASce [21]. Forty-eight hours later, HR 
frequency was estimated by quantifying the frequency of 
GFP positive cells using FACS [21].
Immunocytochemistry
The quantification of nuclear RAD51 foci was 
performed as previously described [3]. Briefly, MCF7 
cells transfected with siRNA targeting CBLC, BRCA2 
or siCONTROL were plated onto cover slips (BD 
Biosciences, Oxford, UK). 16 hours later, cells were 
exposed to 10 Gy ionizing radiation. At 0, 2, 4, 16 and 2 
hours after damage, cells were fixed, permeabilized, then 
immunostained with primary antibody targeting RAD51 
(Santa Cruz Biotech) or phospho-yH2AX (Millipore) and 
detected with a Texas red conjugated secondary antibody. 
DAPI staining was used to detect nuclei. Nuclear foci 
were visualized by confocal microscopy and a minimum 
of 100 fields of view were assessed. Each experiment was 
repeated twice.
cell-based assays
Cell lines were transfected with SMARTpool 
siRNAs (Dharmacon, GE Healthcare) targeting BRCA2 
and CBLC or siCONTROL A (Santa Cruz Biotech) using 
RNAiMax (Invitrogen) transfection reagent. Cell lines 
were infected with GIPZ shRNA constructs packaged as 
lentivirus and after 72hrs selected with 2μg/ml puromycin. 
Clonogenic survival assays were performed as 
previously described [3]. Short-term survival assays were 
performed in 96-well plates. Cells were seeded in 96-well 
plates and drug was added after 24 hours. Cell viability 
was estimated after seven days using Cell-Titre Glo 
(Promega). Surviving fractions (SFs) were calculated and 
drug sensitivity curves plotted as previously described [3].
Quantitative rt-Pcr
Cells were transfected with CBLC cDNA expression 
pCMV6 construct (Origene) then 24 hours later either 
Oncotarget10757www.impactjournals.com/oncotarget
infected with CBLC or control shRNA or transfected 
with CBLC or control siRNA. Quantitative RT-PCR was 
carried out using Assay-on-Demand primer/probe sets 
(Applied Biosystems). Gene expression was calculated 
relative to the expression of GAPDH, and adjusted relative 
to expression in shCONTROL or siCONTROL infected 
cells.
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